Kevin Outterson, J.D., LL.M., is Professor of Law and Austin B. Fletcher Professor of Law at Boston University, where he co-directs the Health Law Program and leads the Social Innovation on Drug Resistance program. He is also the founding Executive Director and Principal Investigator of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership funded by the U.S., U.K., and German governments, Wellcome and the Bill & Melinda Gates Foundation. Its mission is to accelerate a diverse portfolio of innovative antibacterial products toward clinical development and regulatory approval. The CARB-X portfolio is the world’s most scientifically diverse, early development pipeline of new antibacterial therapeutics, diagnostics, and prevention. CARB-X is the only global partnership that includes prevention, diagnosis, and treatment of life-threatening bacterial infections. CARB-X has been awarded over $800 million in grants with Professor Outterson as Principal Investigator.